The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Among patients with nonmetastatic, muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant cisplatin-based combination chemotherapy (NAC) plus bladder-saving concurrent chemoradiation ...

Patients were randomly assigned to receive either neoadjuvant mitomycin C or no neoadjuvant therapy (control arm) prior to TURBT. In the experimental arm, patients underwent cystoscopy and tumor ...

Meeting Coverage > GuCS Expert Video Roundtable Latest on Neoadjuvant Immunotherapy in Muscle-Invasive Bladder Cancer — Matthew Galsky, MD, leads a discussion with Guru Sonpavde, MD, and John ...

Bladder Preservation in Muscle-Invasive Bladder Cancer. ... [to neoadjuvant therapy]," study author Daniel Geynisman, MD, of Fox Chase Cancer Center in Philadelphia, told MedPage Today.

In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

Background: The goal of neoadjuvant therapy for bladder cancer is to improve pathological outcomes and provide patients with the opportunity to preserve the bladder. Disitamab Vedotin, a HER2-targeted ...

In early corporate news, AstraZeneca receives EU approval for a bladder cancer therapy, and a subdued housing market leaves MJ Gleeson eyeing adjusted pretax profit at the lower end of current market ...

References: Imfinzi ® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer. News release. AstraZeneca. March 31, 2025 ...

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may ...

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC. https://pmc.ncbi.nlm.nih ...

And, with 1063 participants, it is the largest study ever undertaken in muscle-invasive bladder cancer, noted Powles. The patient population had classic muscle-invasive disease (clinical tumor ...